{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:51:02Z","timestamp":1783619462560,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2025.103050","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:22:18Z","timestamp":1763630538000},"page":"103050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":false,"given":"Sandip Pravin","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Mino-Kenudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Sethakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2025.103050_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103050_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103050_b0015","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000517438","article-title":"The rise of the TROP2-targeting agents in NSCLC: new options on the horizon","volume":"99","author":"Ahmed","year":"2021","journal-title":"Oncology"},{"issue":"29","key":"10.1016\/j.ctrv.2025.103050_b0020","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103050_b0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103050_b0030","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103050_b0035","first-page":"188902","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochem Biophys Acta"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103050_b0040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14712598.2023.2198087","article-title":"Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer","volume":"23","author":"Belluomini","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"48","key":"10.1016\/j.ctrv.2025.103050_b0045","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.103050_b0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.ctrv.2025.103050_b0055","unstructured":"TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection, for intravenous use. Prescribing information. Gilead Sciences, Inc; 2023. Accessed February 1, 2024. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf."},{"key":"10.1016\/j.ctrv.2025.103050_b0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103050_b0065","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00432-021-03784-3","article-title":"Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments","volume":"148","author":"Omori","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103050_b0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/ol.2013.1368","article-title":"Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma","volume":"6","author":"Jiang","year":"2013","journal-title":"Oncol Lett"},{"issue":"17","key":"10.1016\/j.ctrv.2025.103050_b0075","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.103050_b0080","doi-asserted-by":"crossref","first-page":"657545","DOI":"10.3389\/fonc.2021.657545","article-title":"First-line treatment options for PD-L1-negative non-small cell lung cancer: a Bayesian Network meta-analysis","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103050_b0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cllc.2022.06.002","article-title":"Treatment considerations for patients with advanced squamous cell carcinoma of the lung","volume":"23","author":"Santos","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103050_b0090","doi-asserted-by":"crossref","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103050_b0095","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103050_b0100","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.103050_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8548","article-title":"Datopotamab deruxtecan (Dato-DXd) in Chinese patients with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the Phase 1\/2 TROPION-PanTumor2 study. Presented at","author":"Sun","year":"2024","journal-title":"American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103050_b0110","doi-asserted-by":"crossref","unstructured":"Ahn M.J., Tanaka K., Paz-Ares L., Cornelissen R. Girard N., Pons-Tostivint E., et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2024:Jco2401544.","DOI":"10.1016\/j.annonc.2023.10.588"},{"key":"10.1016\/j.ctrv.2025.103050_b0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8501","article-title":"ICARUS-LUNG01: A phase 2 Study of Dato-DXd in patients with previously treated advanced NSCLC, with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. Presented at","author":"Planchard","year":"2024","journal-title":"American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103050_b0120","unstructured":"Datopotamab (DS-1062a) in Advanced and\/\u200bor Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01). https:\/\/clinicaltrials.gov\/study\/NCT04940325. Accessed August 22, 2024."},{"issue":"10","key":"10.1016\/j.ctrv.2025.103050_b0125","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103050_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103050_b0135","unstructured":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04526691. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8501","article-title":"TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC)","author":"Levy","year":"2025","journal-title":"Presented at American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103050_b0145","first-page":"2","article-title":"TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). Presented at","author":"Goto","year":"2023","journal-title":"American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103050_b0150","first-page":"7","article-title":"Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. Presented at: World Conference on Lung Cancer","author":"Garassino","year":"2024","journal-title":"September"},{"key":"10.1016\/j.ctrv.2025.103050_b0155","unstructured":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04). https:\/\/www.clinicaltrials.gov\/study\/NCT04612751. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0160","doi-asserted-by":"crossref","unstructured":"Papadopoulos K.P., Bruno D., Kitazono S., Murakami S., Gutierrez M., Wakuda K., et al. OA05.06 Datopotamab deruxtecan (Dato-DXd) + durvalumab \u00b1 carboplatin in advanced\/mNSCLC: initial results from phase 1b TROPION-Lung04. Presented at: World Conference on Lung Cancer; September 9-12, 2023; Singapore..","DOI":"10.1016\/j.jtho.2023.09.043"},{"key":"10.1016\/j.ctrv.2025.103050_b0165","doi-asserted-by":"crossref","unstructured":"Waqar S., Cuppens K. Campelo R., Dziadziuszko R., Carcereny E., Yang T.Y., et al., First-line datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer: Results from TROPION-Lung04 (cohort 5). Poster presented at American Society for Clinical Oncology (ASCO), 2025. McCormick Place, Chicago, IL.","DOI":"10.1200\/JCO.2025.43.16_suppl.8521"},{"key":"10.1016\/j.ctrv.2025.103050_b0170","series-title":"Novel anticancer agents + CT and adjuvant D \u00b1 novel agents in resectable NSCLC. Presented at: World Conference on Lung Cancer","first-page":"7","article-title":"NeoCOAST-2: efficacy and safety of neoadjuvant durvalumab (D) +","author":"Cascone","year":"2024"},{"key":"10.1016\/j.ctrv.2025.103050_b0175","unstructured":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06350097. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0180","unstructured":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06417814. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0185","unstructured":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05555732. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0190","unstructured":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05215340. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0195","unstructured":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC \u2265 50%) and Without Actionable Genomic Alterations (TROPION-Lung10). https:\/\/clinicaltrials.gov\/study\/NCT06357533. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0200","unstructured":"Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05687266. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0205","unstructured":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03944772. Accessed August 22, 2024."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103050_b0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103050_b0215","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103050_b0220","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103050_b0225","unstructured":"Paz-Ares L.G., Juan-Vidal O., Mountzios G.S., Felip E. Reinmuth N., de Marinis F., et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol 2024:JCO.24.00733."},{"key":"10.1016\/j.ctrv.2025.103050_b0230","unstructured":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05186974. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8592","article-title":"Sacituzumab govitecan + pembrolizumab in first-line metastatic non-small cell lung cancer with PD-L1 \u226550%: Cohort A of EVOKE-02. Presented at","author":"Patel","year":"2024","journal-title":"American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103050_b0240","first-page":"7","article-title":"Sacituzumab govitecan + pembrolizumab + carboplatin in 1L metastatic non-small cell lung cancer: the EVOKE-02 study. Presented at: World Conference on Lung Cancer","author":"Gray","year":"2024","journal-title":"September"},{"key":"10.1016\/j.ctrv.2025.103050_b0245","doi-asserted-by":"crossref","unstructured":"Fang W., Wang Q., Cheng Y., Luo Y., Qu X., Zhu H., et al. Sacituzumab tirumotecan (sac-TMT; also known as SKB264\/MK-2870) in combination with KL-A167 (anti\u2014PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. Presented at: American Society of Clinical Oncology; May 31-June 4, 2024; Chicago, IL.","DOI":"10.1200\/JCO.2024.42.16_suppl.8502"},{"key":"10.1016\/j.ctrv.2025.103050_b0250","doi-asserted-by":"crossref","unstructured":"Fang W., Cheng Y., Chen Z., Wang W., Yin Y., Li Y., et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study. Abstract presented at: American Society of Clinical Oncology; June 2-June 6, 2023; Chicago, IL.","DOI":"10.1200\/JCO.2023.41.16_suppl.9114"},{"key":"10.1016\/j.ctrv.2025.103050_b0255","unstructured":"SKB264 Combination Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. https:\/\/clinicaltrials.gov\/study\/NCT05351788. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0260","unstructured":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06074588. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0265","unstructured":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u2265 50% (MK-2870-007). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06170788. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0270","unstructured":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06312137. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0275","unstructured":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06422143. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0280","first-page":"20","article-title":"689P DB-1305 (a Trop-2 targeted antibody-drug conjugate [ADC] in patients with advanced solid tumors: preliminary clinical results from the phase 1\/2a study","author":"Marathe","year":"2023","journal-title":"Presented at European Society of Medical Oncology; October"},{"key":"10.1016\/j.ctrv.2025.103050_b0285","doi-asserted-by":"crossref","unstructured":"Wang J., Wu L., Song Z., Li X., Liu C., Liu T., et al. Abstract CT181: A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors. Cancer Res 2023;83(8_Supplement):CT181-CT181.","DOI":"10.1158\/1538-7445.AM2023-CT181"},{"key":"10.1016\/j.ctrv.2025.103050_b0290","doi-asserted-by":"crossref","unstructured":"He, N., Yang C., Yang Y., Xue Z., Xu J., Zhao L., et al. Abstract LB030: SHR-A1921, a novel TROP-2 ADC with an optimized design and well-balanced profile between efficacy and safety. Cancer Res 2023;83(8_Supplement):LB030-LB030.","DOI":"10.1158\/1538-7445.AM2023-LB030"},{"key":"10.1016\/j.ctrv.2025.103050_b0295","unstructured":"Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06465238. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0300","doi-asserted-by":"crossref","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.103050_b0305","doi-asserted-by":"crossref","unstructured":"Sands J., Lisberg A., Bardia A., Shimizu T., Ahn M-J., Paz-Ares L.G., et al. Analysis of drug-related interstitial lung disease (ILD) in patients treated with datopotamab deruxtecan (Dato-DXd). Presented at: American Society of Clinical Oncology; May 31-June 4, 2024; Chicago, IL.","DOI":"10.1200\/JCO.2024.42.16_suppl.8623"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103050_b0310","doi-asserted-by":"crossref","first-page":"oyaf225","DOI":"10.1093\/oncolo\/oyaf225","article-title":"Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management","volume":"30","author":"Lisberg","year":"2025","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103050_b0315","first-page":"756","article-title":"US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan","volume":"33","author":"Rugo","year":"2025","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103050_b0320","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103050_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.103050_b0330","doi-asserted-by":"crossref","unstructured":"Takegawa N., Nonagase Y., Yonesaka K. Sakai K., Maenishi O., Ogitani Y., et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer 2017;141(8):1682\u20131689.","DOI":"10.1002\/ijc.30870"},{"key":"10.1016\/j.ctrv.2025.103050_b0335","unstructured":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05609968. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0340","unstructured":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04656652. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0345","unstructured":"A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05154604. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0350","unstructured":"Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04484142. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0355","unstructured":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05089734. Accessed August 22, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0360","unstructured":"Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/datopotamab-deruxtecan-improved-progression-free-survival-vs-chemotherapy-in-tropion-lung01-phase-iii-trial.html. Accessed February 5, 2024."},{"key":"10.1016\/j.ctrv.2025.103050_b0365","first-page":"20","author":"Garon","year":"2023","journal-title":"European Society for Medical Oncology; October"},{"key":"10.1016\/j.ctrv.2025.103050_b0370","first-page":"20","article-title":"518MO TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Presented at","author":"Kitazano","year":"2023","journal-title":"European Society for Medical Oncology; October"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103050_b0375","doi-asserted-by":"crossref","first-page":"100970","DOI":"10.1016\/j.esmoop.2023.100970","article-title":"4P optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing","volume":"8","author":"Lin","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.103050_b0380","doi-asserted-by":"crossref","unstructured":"Lisberg A., Ahn M-J., Kitazono S., Cho B.C., Blumenschein G., Shum E., et al. Intracranial efficacy of datopotamab deruxtecan in patients with previously treated advanced\/metastatic non-small cell lung cancer; subgrowth actionable genomic alterations: results from TROPION-Lung05. Presented at: American Society of Clinical Oncology; May 31-June 4, 2024; Chicago, IL.","DOI":"10.1200\/JCO.2024.42.16_suppl.8593"},{"key":"10.1016\/j.ctrv.2025.103050_b0385","doi-asserted-by":"crossref","unstructured":"Pons-Tostivint E., Okamoto I., Sands J., Girard N., Cornelissen R., Hong M.H., et al. Dato-DXd vs docetaxel in patients with advanced nonsquamous non-small cell lung cancer with brain metastases: results from TROPION-Lung01. Presented at: European Society for Medical Oncology; September 13-17, 2024; Barcelona, Spain.","DOI":"10.1016\/j.annonc.2024.08.1369"},{"key":"10.1016\/j.ctrv.2025.103050_b0390","unstructured":"First-in-human Study of DB-1305\/BNT325 for Advanced\/Metastatic Solid Tumors. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05438329. Accessed August 22, 2024."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:57:00Z","timestamp":1770479820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":78,"alternative-id":["S0305737225001720"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103050","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103050"}}